Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: Pathogenic mechanisms and diagnosis

European Journal of Haematology

Volumn 94, Issue 1, 2015, Pages 67-73

  Shu, Tingting ^a   Jing, Changwen ^b   Lv, Zhigang ^a   Xie, Yuchun ^a   Xu, Jiaren ^a   Wu, Jianzhong ^b  

^a Jiangsu Province Official Hospital   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Anemia; Anemia of chronic disease; Hepcidin; Iron; Iron deficiency anemia; Tumor

Indexed keywords

HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; IRON; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; ANEMIA; ANEMIA OF CHRONIC DISEASE; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BONE MARROW BIOPSY; CHRONIC DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; AGED; ANEMIA, IRON-DEFICIENCY; BLOOD; COMPLICATION; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDY;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; ERYTHROCYTE INDICES; FEMALE; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84922906571     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12402     Document Type: Article

References (28)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306.
2. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005;69(Suppl. 2):2-7.
3. Calabrich A, Katz A. Management of anemia in cancer patients. Future Oncol 2011;7:507-17.
4. Rodgers GM 3rd, Becker PS, Blinder M, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10:628-53.
5. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007;64(3 Suppl. 2):S5-13; quiz S28-30.
6. Baribeault D, Auerbach M. Iron replacement therapy in cancer-related anemia. Am J Health Syst Pharm 2011;68(10 Suppl. 1):S4-14; quiz S5-6.
7. Lapointe M. Iron supplementation in the intensive care unit: when, how much, and by what route? Crit Care 2004;8(Suppl. 2):S37-41.
8. Merlini L, Carteni G, Iacobelli S, Stelitano C, Airoldi M, Balcke P, Keil F, Haslbauer F, Belton L, Pujol B. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. Cancer Manag Res 2013;5:205-14.
9. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71.
10. Kenneth K, Marshall AL, Ernest B, Thomas JK, Uri S, Josef TP. Williams Hematology, 8th edn. New York, NY: McGraw-Hill press; 2010:617-24.
11. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-76.
12. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-8.
13. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-50.
14. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-10.
15. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012;61:933-52.
16. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43.
17. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86.
18. De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, Ganz T, Musci G, Kaplan J. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007;18:2569-78.
19. van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2011;63:3672-80.
20. World Health Organisation. Nutritional Anemia: Report of WHO Scientific Group. Geneva, Switzerland: World health Organisation; 1968.
21. Watanabe K, Matsumoto A. Staining for iron. Rinsho Byori 1978;34:102-11.
22. Cheng PP, Jiao XY, Wang XH, Lin JH, Cai YM. Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia. Clin Exp Med 2011;11:33-42.
23. Abdel-Khalek MA, El-Barbary AM, Essa SA, Ghobashi AS. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 2011;38:2153-9.
24. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, Nemeth E, Grand RJ, Weinstein DA. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006;12:1101-6.
25. Geerts I, Vermeersch P, Joosten E. Evaluation of the first commercial hepcidin ELISA for the differential diagnosis of anemia of chronic disease and iron deficiency anemia in hospitalized geriatric patients. ISRN hematology 2012;2012:567491.
26. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012;87:392-400.
27. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
28. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008;25:12-21.